CML IDST
Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool

Released: January 07, 2025

Expiration: January 06, 2026

About This Tool & Disclaimer

Clinical Care Options, LLC, is grateful to Daniel J. DeAngelo, MD, PhD; Michael J. Mauro, MD; Neil P. Shah, MD, PhD; B. Douglas Smith, MD; and Tiffany N. Tanaka, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created between October and December 2024 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management decisions based on recommended monitoring and achievement of treatment response milestones to BCR-ABL1 inhibitors in patients with chronic-phase CML.

A series of pull-down menus allows the user to select factors that are necessary to consider when making a decision to switch therapy. It should be noted that these factors are not exclusive when monitoring response to first-line BCR-ABL1 inhibitor therapy and making a decision to change therapy. Many other considerations that are not included in this tool also should be considered, if appropriate, when making a decision of whether to switch treatments.

This tool assumes we have a "standard" patient with CML in chronic phase, but with no additional features or specific comorbidities that would affect treatment choice other than those described when entering the patient details.

Based on the characteristics entered, the tool will display expert-based recommendations for that specific patient case.

After viewing the recommendations from the Expert Insight panel, the tool will prompt the user on whether the recommendations will confirm or change their management plans.

Users are able to print out a complete report of their patient along with the Expert Insight recommendations and supporting data.

©2025 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on the optimal management of patients with CML in chronic phase using TKIs. The information provided is based on guideline recommendations and expert guidance of Daniel J. DeAngelo, MD, PhD; Michael J. Mauro, MD; Neil P. Shah, MD, PhD; B. Douglas Smith, MD; and Tiffany N. Tanaka, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Guidance on Monitoring Response to BCR-ABL1 Inhibitors in CML: An Interactive Decision Support Tool” has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

©2025 Clinical Care Options, LLC. All rights reserved.

Program Content